Nature Communications (Jul 2022)

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

  • Aditya Bardia,
  • Sarat Chandarlapaty,
  • Hannah M. Linden,
  • Gary A. Ulaner,
  • Alice Gosselin,
  • Sylvaine Cartot-Cotton,
  • Patrick Cohen,
  • Séverine Doroumian,
  • Gautier Paux,
  • Marina Celanovic,
  • Vasiliki Pelekanou,
  • Jeffrey E. Ming,
  • Nils Ternès,
  • Monsif Bouaboula,
  • Joon Sang Lee,
  • Anne-Laure Bauchet,
  • Mario Campone

DOI
https://doi.org/10.1038/s41467-022-31668-8
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

There is a need for potent and non-toxic estrogen receptor (ER) antagonists to overcome the limitations of existing endocrine therapies. Here the authors report the results from Arm 1 of the Phase 1/2 study (AMEERA-1) among postmenopausal women with ER+/HER2− advanced breast cancer, which evaluates the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of amcenestrant administered as monotherapy.